Work

Beyond antigen dependence: Improving the therapeutic window of a signal 1 booster for adoptive cell therapy in solid tumors

Year: 2026

Type: article

Abstract: CAR T cell therapy has transformed the treatment of several hematologic malignancies, yet comparable success in solid tumors remains elusive because of heterogeneous antigen expression, restricted T cell trafficking, and an immunosuppressive tumor microenvironment (TME) that limits T cell activation, expansion, persistence, and effector function.1,2 Insufficient access to tumor antigen can further limit signal 1 and compromise engineered T cell fitness. Pharmacologically inducible MyD88/CD40 signaling modules have been developed to provide controlled activation and enhance CAR T cell activity.

Source: Molecular Therapy Oncology

DOI: 10.1016/j.omton.2026.201360

Authors: Angelis M. Morales Rivera, Jiasen He, Candelaria Gomez-Manzano, Juan Fueyo, Hong Jiang

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900